Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 1.00 |
| ▸ | INSR | P06213 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | LTK | P29376 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 2/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 1.00 |
| ▸ | MERTK | Q12866 | 2/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21206279 | 1.00 | ALK (1.00) | ALKINSRLCKLTKAXL | |
| SCHEMBL19328243 | 1.00 | ALK (1.00) | ALKINSRLCKLTKAXL | |
| SCHEMBL24046243 | 1.00 | ALK (1.00) | ALKINSRLCKLTKAXL | |
| SCHEMBL23810096 | 0.95 | ALK (0.90) | ALKINSRLCKLTKAXL | |
| SCHEMBL23810121 | 0.95 | ALK (0.90) | ALKINSRLCKLTKAXL | |
| SCHEMBL23915691 | 0.91 | ALK (0.88) | ALKINSRLCKLTKAXL | |
| SCHEMBL21135589 | 0.91 | ALK (0.88) | ALKINSRLCKLTKAXL | |
| SCHEMBL21759921 | 0.91 | ALK (1.00) | ALKINSRLCKLTKAXL | |
| SCHEMBL24046489 | 0.91 | ALK (1.00) | ALKINSRLCKLTKAXL | |
| SCHEMBL573767 | 0.89 | ALK (0.82) | ALKINSRLCKLTKAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2021-06-03 | — | — | US | claimed |
| US-20210023086-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | LOXO ONCOLOGY, INC. | 2021-01-28 | — | — | US | claimed |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2020-07-28 | — | — | US | claimed |
| US-20170260589-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2017-09-14 | — | — | US | claimed |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10907215-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20210023086-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | LOXO ONCOLOGY, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10655186-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190247398-A1 | FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR | LOXO ONCOLOGY, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10378068-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10370727-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180142306-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180119228-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20180030549-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20180030548-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20170260589-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030548-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | ALK 89/4885INSR 2294/4885LCK 247/4885 |
| US-20180119228-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | ALK 96/4885INSR 2261/4885LCK 251/4885 |
| US-10907215-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | ALK 96/4885INSR 2261/4885LCK 251/4885 |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | ALK 89/4885INSR 2294/4885LCK 247/4885 |
| US-20190247398-A1 | FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR | DMPK, TTK, GAK | ALK 143/4885INSR 663/4885LCK 67/4885 |
| US-20180030549-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | ALK 89/4885INSR 2294/4885LCK 247/4885 |
| US-10370727-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | ALK 96/4885INSR 2261/4885LCK 251/4885 |
| US-20180142306-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | ALK 96/4885INSR 2261/4885LCK 251/4885 |
| US-10655186-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | ALK 89/4885INSR 2294/4885LCK 247/4885 |
| US-20210023086-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | TP53, NCOA3, NCOA1 | ALK 369/4885INSR 1101/4885LCK 136/4885 |
| US-10378068-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | ALK 89/4885INSR 2294/4885LCK 247/4885 |
| US-20170260589-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | ALK 96/4885INSR 2261/4885LCK 251/4885 |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | ALK 89/4885INSR 2294/4885LCK 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.